The company has not filed an annual or quarterly report since its Q2 FY2017 10-Q, filed Aug 9, 2017. Its latest SEC filing is a SC 13G/A from Feb 14, 2018.
10-Q for Q2 FY2017, filed Aug 9, 2017
The sections below describe the company as of the FY2016 annual report.
Provides drug discovery and development, pharmaceutical ingredient and drug-product manufacturing, and analytical testing services to pharmaceutical and biotechnology companies, government and nonprofit research organizations, and medical-device and related-industry companies.
10-K for FY2016, filed Mar 16, 2017We are a leading global contract research and manufacturing organization providing customers fully integrated drug discovery, development…View ↗
We perform services and offer solutions in drug discovery and the development, manufacture and testing of pharmaceutical intermediates, API…View ↗
We have organized our business into four distinct segments: DDS, API, DP and Fine Chemicals (“FC”). Our DDS segment provides comprehensive…View ↗
CustomersView ↗
Customers pay for research, development and manufacturing services: fixed-project fees when work is delivered, or monthly and hourly charges as scientists work. Partners may also pay upfront or at milestones, for manufactured products on delivery, and royalties or profit shares tied to product sales.
10-K for FY2016, filed Mar 16, 2017Fixed-Fee. Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed…View ↗
Full-time Equivalent (“FTE”). An FTE agreement establishes the number of Company employees contracted for a project or a series of…View ↗
These contracts involve the Company’s scientists providing services on a “best efforts” basis on a project that may involve a research…View ↗
Time and Materials. Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for chemicals and…View ↗
The Company enters into collaboration arrangements with third parties for the development and manufacture of certain products and/or…View ↗
The Company recognizes revenue for payments received for services performed under these arrangements as contract revenue in accordance with…View ↗
$570.5M
10-K for FY2016, filed Mar 17, 2017
$570.5M ↗Pharmaceutical and biotechnology companies, government research entities and nonprofits buy services directly through sales staff and technical contacts; the company also serves medical-device and related-industry businesses.
10-K for FY2016, filed Mar 16, 2017
Total contract revenue from GE Healthcare (“GE”), the Company’s largest customer, represented 7%, 11% and 13% of the Company’s total…View ↗
No. It lost $70.2M in FY2016.
10-K for FY2016, filed Mar 17, 2017
10-Q for Q2 FY2017, filed Aug 10, 2017
−$10.2MView ↗
8-K, filed Aug 31, 2017
ALBANY, N.Y. – August 31, 2017 – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing…View ↗
Grew. Revenue grew 2.5x in 4 years, from $226.7M in FY2012 to $570.5M in FY2016, about 26% a year.
From proprietary programs to generic collaborations
The earlier report described internal drug-discovery programs that AMRI sought to license to partners. The latest report emphasizes collaborations with pharmaceutical companies on generic products, with revenue from development, supply and potential profit sharing.
10-K for FY2013, filed Mar 17, 2014 10-K for FY2016, filed Mar 16, 2017Since 2014, we have focused on advancing our leadership in the development and manufacture of generic products by entering into multiple…View ↗
Loading...
